New oral vaccine for Alzheimer...( Alzheimer's disease is characterized by...),Health

Alzheimer's disease is characterized by progressive loss of cognitive function due to amyloid-beta (A) deposits in the central nervous system. If these deposits could be stopped or slowed, Alzheimer's disease might become more manageable. In the current issue of the Journal of Alzheimer's Disease, a novel paper from researchers from the National Institute for Longevity Sciences, NCGG, Japan and Center for Neurological Diseases, Brigham & Women's Hospital, Harvard Institute of Medicine shows that a new oral vaccine treatment is effective in reducing Alzheimer's disease pathology.

Immunization results from the production of antibodies which attack the harmful agent, using the body's own defenses to remove the threat. In an earlier immunization study, 6 percent of the subjects developed acute meningoencephalitis, most likely caused by autoimmune T-cell activation. This caused the trial to be stopped. By developing vaccines that can minimize this T-cell activation while retaining the production of A-antibodies, a safer treatment might result.

The researchers attached A DNA to an adeno-associated virus vector and administered this vaccine to mice orally. Not only were the A levels decreased, but the T-cell immune response was significantly reduced. A single dose of this vaccine enhanced the production of A-antibodies for more than 6 months. Immunohistochemistry of the mouse brain tissue showed that the extra-cellular amyloid deposits were clearly decreased compared to the non-treated mouse.

Hideo Hara, M.D, writes "This new oral vaccine does not induce strong T cell immune reactions, and hence it could reduce the side effect of such meningoencephalitisThis new therapy seems to be effective for prevention and treatment of Alzheimer's disease."

The article is "Development of a safe oral A vaccine using recombinant adeno-associated virus vector for Alzheimer's disease" by Hideo Hara, Alon Monsonego, Katsutoshi Yuasa, Kayo Adachi, Xiao Xiao,
'"/>

Contact: George Perry, Ph.D.
george.perry@case.edu
216-368-2488
Case Western Reserve University
25-Oct-2004

Page: 1 2
Related medicine news :

1. Pitt marks 50th anniversary of its Salk polio vaccine with reunion, scientific symposium
2. NIAID initiates trial of experimental avian flu vaccine
3. Study finds majority of women willing to accept cervical cancer vaccine for self and children
4. Invasive pneumonia and antibiotic resistance decreased after childhood vaccine introduced
5. Earlier use of prostate cancer vaccines urged by Hopkins scientists
6. Researchers close in on breast cancer vaccine
7. EuroVacc 02 HIV vaccine trial begins in February 2005
8. Varicella vaccine effective on chicken pox; Impact on herpes zoster unclear
9. Pathogen-mimicking vaccine as strategy for cancer therapy
10. HIV vaccine trial breaks ground for future research
11. First US kidney cancer vaccine trial underway at Columbia